Mapping 21 CFR to ISO 13485 "Regulatory Requirements" Under the QMSR
A practical method for US manufacturers to identify which FDA 21 CFR requirements fill the "applicable regulatory requirements" references in ISO 13485:2016, and which US-only procedures to add.

ISO 13485:2016 uses the phrase "applicable regulatory requirements" throughout, but it never tells you which regulations those are. That was left to each jurisdiction. Since February 2, 2026, FDA's Quality Management System Regulation (QMSR) incorporates ISO 13485 by reference into 21 CFR Part 820. For a US manufacturer, those references now point to Title 21 of the Code of Federal Regulations.
This article shows how to map them, so your ISO 13485 quality system clearly covers the US requirements an FDA investigator will look for.
Why the mapping matters now
Many companies certified to ISO 13485 assume certification means FDA compliance. It does not. The QMSR adds US-specific definitions and requirements (for example 820.10, 820.35 and 820.45). Several other 21 CFR Parts sit outside the standard entirely: medical device reporting, corrections and removals, registration and listing, and UDI.
If your QMS never names these as its "applicable regulatory requirements," procedures may be missing, and an investigator will notice.
Step 1: Build a regulatory requirements register
Start with one controlled list of the 21 CFR Parts that apply to your company and devices:
- **Part 820** — QMSR
- **Part 801** — labeling, and **Part 830** — UDI
- **Part 803** — medical device reporting (MDR)
- **Part 806** — corrections and removals
- **Part 807** — registration, listing and 510(k)
- **Parts 812 and 814** — IDE and PMA, where relevant
- **Parts 821 and 822** — tracking and postmarket surveillance, only when FDA orders them
- **Part 11** — electronic records and signatures
- **Part 7** — recalls
Clause 4.1.1 expects you to document your role under these requirements. Record whether you are a manufacturer, specification developer, contract manufacturer or relabeler.
Step 2: Map clause by clause
Go through each ISO 13485 clause that mentions regulatory requirements and note the 21 CFR Parts that fill it:
Swipe horizontally to see all columns.
| ISO 13485:2016 clause | 21 CFR requirement(s) | What to address |
|---|---|---|
| 4.1.1 General | 820.10; Part 807 | Document your US role(s) and applicable Parts |
| 4.2.3 Medical device file | 801, 830; 807 / 814 | Labeling, UDI and marketing authorization basis |
| 7.2.3 Communication | 803, 806; Part 7 | MDR, correction/removal and recall communications |
| 7.3.9 Design changes | 807.81(a)(3); 814.39 | Documented new-510(k) or PMA-supplement decision |
This is an illustrative crosswalk, not an FDA-endorsed mapping. Confirm it with qualified reviewers for your devices.
Step 3: Check the reverse direction
Then start from each regulation and ask: does ISO 13485 wording alone create this procedure? For Part 803 the answer is no. You need written MDR procedures (803.17) with 30-day and 5-day timelines. The same applies to Part 806 reports, annual registration under Part 807, and GUDID submissions under Part 830.
Step 4: Close the gaps and rehearse
Record each gap with an owner, priority and due date. Then rehearse the questions an investigator may ask under Compliance Program 7382.850, such as: *"Show me how your QMS identifies the US regulatory requirements that apply to this device."*
The kit
The 21 CFR to ISO 13485 Regulatory Requirements Mapping Kit turns these steps into a protected Excel workbook. It includes a clause crosswalk, a reverse map, US-only additions, a procedure register, a gap action plan, an inspection checklist, and overlays for Class I, 510(k), PMA, software and combination products. It is a one-time purchase per company workspace. Get the kit.
*Educational planning content, not legal advice. ISO 13485 clauses are referenced by number and title only.* The full crosswalk and tracking fields are included in the paid kit.
New to a term? See the MedTech regulatory glossary for plain-English definitions.
Follow MedTech Insights
New articles on FDA 510(k) and De Novo pathways, CE Mark and EU MDR, and device reimbursement — sent to your inbox as they publish.

